AcelRx Pharmaceuticals (ACRX) Rating Increased to Buy at Zacks Investment Research

AcelRx Pharmaceuticals (NASDAQ:ACRX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, December 27th. The firm currently has a $2.25 target price on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price objective suggests a potential upside of 9.76% from the stock’s current price.

According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “

Several other research firms have also recently weighed in on ACRX. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of AcelRx Pharmaceuticals in a report on Tuesday, October 3rd. Roth Capital set a $8.00 target price on shares of AcelRx Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, October 12th. ValuEngine upgraded shares of AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, September 26th. Royal Bank of Canada dropped their target price on shares of AcelRx Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating on the stock in a research note on Friday, October 13th. Finally, Jefferies Group cut shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $6.21.

AcelRx Pharmaceuticals (NASDAQ:ACRX) traded up $0.02 during trading on Wednesday, reaching $2.05. 159,591 shares of the company traded hands, compared to its average volume of 394,415. AcelRx Pharmaceuticals has a 1-year low of $1.55 and a 1-year high of $5.75. The stock has a market capitalization of $103.19, a PE ratio of -1.83 and a beta of 2.96. The company has a current ratio of 4.78, a quick ratio of 4.71 and a debt-to-equity ratio of -0.43.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). equities analysts predict that AcelRx Pharmaceuticals will post -1.06 EPS for the current fiscal year.

In related news, Director Mark G. Edwards bought 30,000 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were purchased at an average cost of $1.90 per share, for a total transaction of $57,000.00. Following the completion of the purchase, the director now directly owns 150,000 shares in the company, valued at $285,000. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 28.10% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Geller Family Office Services LLC bought a new stake in shares of AcelRx Pharmaceuticals in the third quarter valued at approximately $460,000. Perennial Advisors LLC bought a new stake in shares of AcelRx Pharmaceuticals in the third quarter valued at approximately $138,000. Goldman Sachs Group Inc. bought a new stake in shares of AcelRx Pharmaceuticals in the second quarter valued at approximately $530,000. Finally, Virtu KCG Holdings LLC raised its position in shares of AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after purchasing an additional 101,742 shares during the period. 13.70% of the stock is currently owned by institutional investors.

WARNING: This piece of content was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/01/20/acelrx-pharmaceuticals-acrx-upgraded-by-zacks-investment-research-to-buy.html.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply